Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Positive 12-week induction topline data from Phase 2 SKYLINE Part A for SPY003 in moderately-to-severely active ulcerative colitis.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive 12-week induction topline data from Phase 2 SKYLINE Part A for SPY003 in moderately-to-severely active ulcerative colitis
- SPY003 is an anti-IL-23 therapy, positioning Spyre in the competitive UC biologics market
- Results announced September 8, 2026; detailed efficacy and safety data available in Exhibit 99.1
Item 8.01 · Other Events
- SPY003 achieved Phase 2 UC proof-of-concept, reducing RHI 10.0 points at Week 12 versus baseline, p<0.0001
- Clinical remission reached 20%, endoscopic improvement 30%, and modified Mayo Score improved 3.5 points
- Safety profile supports combination development: 43% reported AEs, 7% SAEs, no drug-related SAEs, discontinuations, or deaths
- Part B is enrolling across monotherapy and combination arms SPY120, SPY130, and SPY230, with topline data expected in 2027
- Upcoming catalysts include SKYWAY results in 4Q 2026 and SKYLIGHT results in late 2027 or early 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.